Androscience Corporation
Records under this name other than patents Androscience Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Androscience Corporation
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,710,272 | Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,000,222 | Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 9,259,402 | Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyI)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,202,905 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,236,852 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,359,279 | Treatment of cancer, inflammatory disease, and autoimmune disease Formerly held Lapsed on the fee record Ended Jun 7, 2024 · From the USPTO record | Lapsed on the fee record | Ended Jun 7, 2024 | From the USPTO record |
| US 8,198,323 | Curcumin analogues and uses thereof Term ended Term ended May 5, 2023 · From the USPTO record | Term ended | Term ended May 5, 2023 | From the USPTO record |
| US 8,822,732 | 1,5-diphenyl-penta-1,4-dien-3-one compounds Formerly held Lapsed on the fee record Ended Sep 2, 2022 · From the USPTO record | Lapsed on the fee record | Ended Sep 2, 2022 | From the USPTO record |
| US 6,790,979 | Novel Curcumin Analogues and Uses Thereof Term ended Term ended Apr 17, 2022 · High confidence | Term ended | Term ended Apr 17, 2022 | High confidence |
| US 7,355,081 | Novel Curcumin Analogues and Uses Thereof Formerly held Term ended Term ended Apr 17, 2022 · Medium confidence | Term ended | Term ended Apr 17, 2022 | Medium confidence |